盈利预期

Search documents
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-05-06 12:15
Core Insights - Esperion Therapeutics reported a quarterly loss of $0.21 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.18, and a decline from earnings of $0.34 per share a year ago, indicating an earnings surprise of -16.67% [1] - The company generated revenues of $65 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 12.58%, but down from $137.74 million year-over-year [2] - Esperion's shares have declined approximately 52.3% since the beginning of the year, contrasting with the S&P 500's decline of -3.9% [3] Earnings Outlook - The future performance of Esperion's stock will largely depend on management's commentary during the earnings call and the revisions of earnings estimates [4][5] - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $64.91 million, and for the current fiscal year, it is -$0.09 on revenues of $338.51 million [7] Industry Context - The Medical - Drugs industry, to which Esperion belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Metagenomi, is expected to report a quarterly loss of $0.62 per share, reflecting a year-over-year change of +47.9%, with revenues anticipated to be $8.75 million, down 21.6% from the previous year [9]
Crescent Energy (CRGY) Q1 Earnings and Revenues Beat Estimates
ZACKS· 2025-05-05 23:35
Core Viewpoint - Crescent Energy (CRGY) reported quarterly earnings of $0.56 per share, exceeding the Zacks Consensus Estimate of $0.47 per share, and showing an increase from $0.46 per share a year ago, representing an earnings surprise of 19.15% [1][2] Financial Performance - The company posted revenues of $950.17 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.40%, and up from $657.47 million year-over-year [2] - Over the last four quarters, Crescent Energy has exceeded consensus EPS estimates four times and topped consensus revenue estimates two times [2] Stock Performance and Outlook - Crescent Energy shares have declined approximately 41% since the beginning of the year, compared to a decline of 3.3% for the S&P 500 [3] - The company's earnings outlook is uncertain, with current consensus EPS estimates at $0.26 for the upcoming quarter and $1.66 for the current fiscal year, with revenues expected to be $898.17 million and $3.7 billion respectively [7] Industry Context - The Alternative Energy - Other industry, to which Crescent Energy belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Crescent Energy's stock performance [5]
Hims & Hers Health, Inc. (HIMS) Beats Q1 Earnings and Revenue Estimates
ZACKS· 2025-05-05 22:40
Core Viewpoint - Hims & Hers Health, Inc. reported strong quarterly earnings, exceeding expectations and showing significant year-over-year growth in both earnings and revenues [1][2]. Financial Performance - The company reported earnings of $0.20 per share, surpassing the Zacks Consensus Estimate of $0.12 per share, and up from $0.05 per share a year ago, representing an earnings surprise of 66.67% [1]. - Revenues for the quarter ended March 2025 were $586.01 million, exceeding the Zacks Consensus Estimate by 8.91%, and significantly higher than the $278.17 million reported in the same quarter last year [2]. Stock Performance - Hims & Hers Health shares have increased approximately 68.8% since the beginning of the year, contrasting with a decline of 3.3% in the S&P 500 [3]. - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations for it to outperform the market in the near future [6]. Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.15 on revenues of $562.21 million, and for the current fiscal year, it is $0.64 on revenues of $2.33 billion [7]. - The industry outlook is favorable, with the Medical Info Systems sector ranking in the top 28% of Zacks industries, suggesting strong potential for stock performance [8].
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-05-05 22:20
Si-Bone (SIBN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 37.50%. A quarter ago, it was expected that this medical device maker would post a loss of $0.16 per share when it actually produced a loss of $0.11, delivering a surprise of 31.25%.Over the last four quarters, the company has sur ...
Verisk Set to Report Q1 Earnings: Here's What You Should Know
ZACKS· 2025-05-05 16:46
Core Viewpoint - Verisk (VRSK) is set to release its Q1 fiscal 2025 results on May 7, with expectations of revenue growth and earnings increase compared to the previous year [1][2][4]. Revenue Expectations - The Zacks Consensus Estimate for Verisk's revenues is $745 million, reflecting a 6.5% increase from the same quarter last year [2]. - Revenue estimates from the United States are projected at $612.4 million, indicating a year-over-year growth of 5.4% [3]. - Expected revenues from the U.K. are $55.7 million, showing a 7.3% increase from the prior year [3]. - Revenues from other countries are estimated to rise by 13.5% to $80.6 million [3]. Earnings Expectations - The consensus estimate for earnings per share is $1.67, suggesting a 2.5% growth from the previous year's figure [4]. - Strong margin expansion is anticipated to contribute positively to the bottom line [4]. Earnings Prediction Model - The current model indicates that Verisk may not achieve an earnings beat this quarter, with an Earnings ESP of -2.34% and a Zacks Rank of 4 (Sell) [5].
MTD Q1 Earnings Top Estimates, Sales Decline Y/Y, Shares Rise
ZACKS· 2025-05-05 15:35
Core Viewpoint - Mettler-Toledo International (MTD) reported strong first-quarter 2025 results, with a positive outlook driven by growth in the laboratory business and recent innovations, despite a year-over-year decline in earnings and sales [1][2]. Financial Performance - Adjusted earnings for Q1 2025 were $8.19 per share, exceeding the Zacks Consensus Estimate by 3.67%, although this represents a 7.9% decline year-over-year [1]. - Net sales reached $883.744 million, surpassing the Zacks Consensus Estimate by 1%, but declined 5% on a reported basis and 3% on a local currency basis compared to the previous year [2]. Segment Performance - MTD's revenues were categorized into three segments: Laboratory Instruments ($500 million, 56.6% of net sales), Industrial Instruments ($341 million, 38.6%), and Food Retail ($42 million, 4.8%) [3]. - The Laboratory and Industrial segments experienced a year-over-year decline of 3% and 1% respectively in local currency, while the Food Retail segment saw a 12% decrease [3]. Geographic Sales Breakdown - Sales distribution included $378 million (42.8%) from the Americas, $248 million (28.1%) from Europe, and $258 million (29.2%) from Asia/Rest of the World [4]. - Year-over-year sales in the Americas and Asia/Rest of the World declined by 1% and 2% respectively, while Europe experienced a 7% decline [4]. Operating Results - The gross margin improved to 59.6%, an increase of 40 basis points year-over-year [5]. - Research & development (R&D) expenses were $46.3 million, a slight decrease of 0.1% from the previous year, while selling, general & administrative (SG&A) expenses rose by 3.6% to $242.8 million [5]. - The adjusted operating margin was reported at 26.8%, down 210 basis points from the prior year [6]. Balance Sheet & Cash Flow - As of March 31, 2025, Mettler-Toledo had cash and cash equivalents of $64.291 million, an increase from $59.362 million at the end of 2024 [7]. - Long-term debt stood at $1.89 billion, with cash generated from operating activities at $194.5 million, down from $266.2 million in the previous quarter [7]. Future Guidance - For Q2 2025, Mettler-Toledo expects sales to increase by 0-1% in local currency compared to the previous year, with adjusted earnings projected between $9.45 and $9.70 per share, reflecting a growth rate of down 2% to up 1% [8]. - The Zacks Consensus Estimate for Q2 revenues is $949.6 million, indicating a year-over-year increase of 0.3%, while the consensus for earnings is $10.22 per share, representing a 5.91% increase from the previous year [9]. - For the full year 2025, Mettler-Toledo anticipates a sales increase of approximately 1% to 2% in local currency compared to 2024, with adjusted earnings expected between $41.25 and $42 per share, indicating 0-2% growth [10].
为何业绩预报是关键的市场风险
Sou Hu Cai Jing· 2025-05-05 13:27
第一季度财报季总体进展顺利,因为这是特朗普关税政策产生影响之前的最后一个季度。 根据巴克莱银行的数据,标普 500 指数(^GSPC)成分股公司本季度的盈利同比增长 7.9%。盈利超出 预期的平均幅度为 10.2%,而长期平均超出预期幅度为 5.2%。 苹果(AAPL)、字母表公司(GOOG, GOOGL)和微软(MSFT)等家喻户晓的公司,其业绩令华尔 街印象深刻。 但标普 500 指数成分股公司是否能够实现预计 10% 的每股收益增长率仍存疑问,它们的估值前景同样 如此。 考克斯警告称:"我认为让很多华尔街人士担忧的是,感觉最糟糕的情况还在后头。" 从企业高管到普通消费者,每个人都在担心关税带来的影响,投资者在寻找合理估值的过程中,股票市 场也随之大幅波动。 在 4 月初的 "解放日" 之后,股票市场大幅下跌,并在 4 月 7 日触底,随后随着财报陆续公布,股票市 场在当月反弹回升。 可口可乐(KO)董事长兼首席执行官詹姆斯・昆西告诉索齐,谨慎的消费者在超市的购买量有所减 少。 昆西解释道:"疲软就集中在这个方面,我认为这在一定程度上表明了低收入消费者面临的一些购买力 压力,以及一些地缘政治因素的影响。" ...
Root Gears Up to Report Q1 Earnings: Here's What to Expect
ZACKS· 2025-05-05 12:15
Core Insights - Root, Inc. (ROOT) is anticipated to show improvements in both revenue and earnings for Q1 2025, with revenue expected to reach $305 million, reflecting a 19.6% year-over-year growth [1] - The earnings consensus estimate is set at 45 cents per share, indicating a significant year-over-year increase of 207.1%, with a 36.4% upward revision in the past 30 days [2] Revenue and Earnings Estimates - The Zacks Consensus Estimate for ROOT's first-quarter revenues is $305 million, which is a 19.6% increase from the previous year [1] - The earnings estimate for the first quarter is 45 cents per share, which has seen a 36.4% increase in the last month, suggesting a 207.1% year-over-year growth [2][3] Factors Influencing Q1 Results - Expected drivers for revenue growth include higher net premiums earned, improved net investment income, and increased fee income [4] - The increase in policies in force and growth in partnership channels are likely to contribute positively to net premiums earned, with the estimate for first-quarter net investment income at $279 million [5] - The net investment income is projected to rise due to a higher average cash balance and a larger investment portfolio, although some offset may occur due to increased impairments [6] Underwriting and Expenses - Improved underwriting profitability is anticipated due to better pricing and prudent underwriting practices, although recent California wildfires may negatively impact results [7] - Total operating expenses are expected to rise due to higher loss adjustment expenses and increased costs in various operational areas [7]
Wendy's (WEN) Q1 Earnings Match Estimates
ZACKS· 2025-05-02 13:10
Financial Performance - Wendy's reported quarterly earnings of $0.20 per share, matching the Zacks Consensus Estimate, but down from $0.23 per share a year ago [1] - The company posted revenues of $523.47 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 0.10% and down from $534.75 million year-over-year [2] - Over the last four quarters, Wendy's has surpassed consensus EPS estimates just once and topped consensus revenue estimates two times [2][3] Stock Performance - Wendy's shares have declined approximately 23.4% since the beginning of the year, compared to a 4.7% decline in the S&P 500 [3] - The current Zacks Rank for Wendy's is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.28 on revenues of $573.56 million, and for the current fiscal year, it is $0.99 on revenues of $2.24 billion [7] - The outlook for the Retail - Restaurants industry, to which Wendy's belongs, is currently in the bottom 16% of over 250 Zacks industries, which may impact stock performance [8]
Reinsurance Group (RGA) Q1 Earnings Top Estimates
ZACKS· 2025-05-01 23:25
分组1 - Reinsurance Group (RGA) reported quarterly earnings of $5.66 per share, exceeding the Zacks Consensus Estimate of $5.33 per share, but down from $6.02 per share a year ago, representing an earnings surprise of 6.19% [1] - The company posted revenues of $5.34 billion for the quarter ended March 2025, missing the Zacks Consensus Estimate by 6.97%, and down from $6.19 billion year-over-year [2] - Over the last four quarters, RGA has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] 分组2 - RGA shares have declined approximately 12.3% since the beginning of the year, compared to a 5.3% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $5.74 on revenues of $5.88 billion, and for the current fiscal year, it is $22.80 on revenues of $24.34 billion [7] - The Zacks Industry Rank for Insurance - Life Insurance is currently in the bottom 35% of over 250 Zacks industries, indicating potential challenges for the sector [8]